BMC Neuroscience (Nov 2018)

The significance of anti-neuronal antibodies for acute psychiatric disorders: a retrospective case–controlled study

  • Morten B. Schou,
  • Sverre Georg Sæther,
  • Ole Kristian Drange,
  • Karoline Krane-Gartiser,
  • Solveig K. Reitan,
  • Arne E. Vaaler,
  • Daniel Kondziella

DOI
https://doi.org/10.1186/s12868-018-0471-7
Journal volume & issue
Vol. 19, no. 1
pp. 1 – 8

Abstract

Read online

Abstract Background The clinical significance of anti-neuronal antibodies in patients with psychiatric disorders, but without encephalitis, remains unknown. In patients admitted to acute psychiatric inpatient care we aimed to identify clinical features distinguishing anti-neuronal antibody positive patients from matched controls. Results Patients who were serum-positive to N-methyl d-aspartate receptor (NMDAR) (n = 21), contactin-associated protein 2 (CASPR2) (n = 14) and/or glutamic acid decarboxylase 65 (GAD65) (n = 9) antibodies (cases) were age and sex matched (1:2) with serum-negative patients from the same cohort (controls). The prevalence and severity of psychiatric symptoms frequently encountered in NMDAR, CASPR2 and GAD65 antibody associated disorders were compared in cases and controls. NMDAR, CASPR2 and GAD65 antibody positive patients did not differ in their clinical presentation from matched serum negative controls. Conclusion In this cohort, patients with and without NMDAR, CASPR2 and GAD65 antibodies admitted to acute psychiatric inpatient care had similar psychiatric phenotypes. This does not exclude their clinical relevance in subgroups of patients, and studies further investigating the clinical significance of anti-neuronal antibodies in patients with psychiatric symptomatology are needed.

Keywords